Dr. Farago on Opportunities to Investigate Biomarkers for Small Cell Lung Cancer

Anna Farago, MD, PhD, Massachusetts General Hospital Cancer Center, instructor of Medicine at Harvard Medical School, discusses opportunities for the development of biomarkers for patients with small cell lung cancer (SCLC).

There was a panel of patient-derived xenograft (PDX) models of SCLC, which were developed from circulating tumor cells (CTC) using the CTC-iChip and some of them were developed from biopsy specimens.

There is hope that having these laboratory models of the patients with SCLC will give researchers the opportunity to investigate proposed biomarkers of sensitivity to other drugs in lung cancer.